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Abstract 
Background: Recent studies have shown that certain human genetic polymorphisms could be associated with 
susceptibility to tuberculosis (TB) infection and disease. Advances in next generation sequencing include the ability 
to rapidly sequence the entire human exome. These new technologies can be exploited to identify new associations 
of human genetic polymorphisms and TB infection and disease. In this preliminary study we compared two different 
strategies for sequencing of the human exome in a small sample set consisting of three individuals with a history of 
TB disease and two individuals with latent TB infection.
Findings: Sequencing of the entire exome of the five participants using Agilent SureSelect kit resulted in the iden‑
tification of 1611 single nucleotide polymorphisms (SNPs) that were only present in the individuals with a history 
of active TB but not in the latent TB cases. Alternatively, sequencing of 4000 target genes available in the TruSight 
kit resulted in identification of 182 SNPs only present in the active TB cases and not in the latent TB participants. The 
overlap of the two kits was 112 SNPs.
Conclusions: Even though this pilot study was restricted to a small number of participants, we demonstrated the 
feasibility of using exome sequencing technologies to mine potential genetic associations of susceptibility to TB dis‑
ease and presented a number of potential targets that can be further explore in larger research trials.
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Findings
Rationale
Recent studies have shown that certain human genetic 
polymorphisms could be associated with susceptibil-
ity to TB [1–10]. Many of the tested genes identified to-
date are involved directly or indirectly with immune and 
inflammation mechanisms [4–10]. However, it is possible 
that other polymorphisms outside of these target genes 
may be involved in susceptibility to TB. Recent advances 
in sequencing technologies and tools have made it pos-
sible to rapidly sequence the entire coding region of the 
human genome (exome) and allowing the identification 
of novel polymorphisms associated with a particular 
disease, disorder or condition [11–14]. Exome sequenc-
ing has been exploited to evaluate gene variants associ-
ated with certain cancers, however, its use in the study 
of susceptibility to infectious diseases is still limited [15, 
16]. Tuberculosis infection and disease has a long history 
of association with the human race [17, 18] and given its 
intricate relationship with the host, it is not surprising 
that certain genes and gene variants or mutations have 
been thought to be involved in the ability of the host to 
fight the infection and/or halt its progression to disease.
Goal
The main focus of this pilot study was to evaluate the util-
ity of two different kits for exome sequencing as a means 
to identify novel polymorphisms associated with suscep-
tibility to TB. In Toronto, Canada, the largest clusters 
of active TB transmission are associated with the under 
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housed or homeless population [19–21] and therefore 
another goal of the study was to evaluate the feasibility 
to recruit participants in this group, including individuals 
with past history of TB disease as well as individuals with 
a record of TB infection.
Ethics, consent and permission
Ethics approval for this study was granted by the institu-
tional Ethics Research Board at Public Health Ontario, 
file number 2013-038. All participants received and 
signed an informed consent to voluntarily participate in 
this study.
Methods
After ethics approval was obtained, we conducted 
1  month of recruitment at one of Toronto’s inner city 
shelters. In total we recruited nine individuals. Three of 
these had a positive history of active TB disease for which 
the genotyping data indicated their infection was due to 
either one of the four M. tuberculosis strains previously 
associated with this population [19, 22]. The remaining 
six individuals were recruited as potential candidates 
for the latent TB control group, however, only two of 
them had a record of a positive TB skin test indicating 
TB latent infection. The four individuals with no proven 
record of TB infection were not enrolled in the study. 
Blood samples were obtained from all participants and 
used to extract gDNA using the Qiagen QIAamp DNA 
blood mini kit as per the manufacture’s protocol. Two 
different sequencing kits were evaluated, Agilent Sure-
SelectXT Target Enrichment System—Human All Exon 
V5  +  UTRs and Illumina TruSight™ One. Illumina 
TruSight™ One targets 4813 genes, including several 
immune related genes previously shown to be involved in 
TB infection and or host–pathogen interactions. gDNA 
from all participants was used to prepare the libraries 
for each kit as recommended by the manufacturer. Sure-
Select libraries were pooled and sequenced in two lanes 
of an Illumina Hiseq 2500 instrument at the Clinical 
Genomics Centre in Mount Sinai Hospital and TruSight 
libraries were pooled in groups of three and sequenced 
in an Illumina MiSeq at our institutional genomics core. 
Data analysis was performed using the CLC Genomics 
Workbench v7.0 software by mapping the reads to the 
reference Human genome hg19 (GRCh37 Ensemble 74). 
Single nucleotide variants were identified using a quality 
based variant detection with a minimum coverage cutoff 
of 10× and a minimum frequency of 35 % for heterozy-
gous alleles. Variants were annotated using the dbSNP 
database (http://www.ncbi.nlm.nih.gov/snp/). Only SNPs 
identified in the target regions and in all three active TB 
cases, and absent in the two latent TB cases, were kept 
for analysis.
Outcomes
The total number of targets covered with at least a 10× 
coverage ranged from 94.6 to 96  % for the SureSelect 
and 93.8–94.9  % for the TruSight kit. The two enrich-
ment kits performed relatively similar in terms of time 
and cost of library preparation and sequencing costs. 
Promoter regions located outside of the untranslated 
regions (UTRs) are not covered in any of the two kits and 
therefore potential polymorphisms in these regions are 
not identified. However, given the large number of exon 
regions covered by the SureSelect, this kit is ideal to use 
in a discovery assay for the identification of novel poly-
morphisms associated to a given condition.
Using the SureSelect kit we identified 1611 SNPs that 
were only present in the Active TB cases. Using the 
TruSight kit we identified 182 SNPs only present in the 
active TB cases and not in the latent TB participants. The 
overlap of the two kits was 112 SNPs (Additional file 1: 
Table S1). The 70 SNPs found in the TruSight kit data that 
did not overlap with the SureSelect kit were examined in 
more detail. Of these, 21 were in target regions not cov-
ered by the SureSelect kit, 15 were not called in the Sure-
Select data because the ratio of alleles was <35 %, 26 were 
in found in the latent cases but not called in the TruSight 
data due to insufficient coverage, six were not called in 
the SureSelect data due to insufficient coverage and two 
were incorrect calling due to stretches of homopolymers.
Since TB is an infectious disease with a complex inter-
action between host, pathogen and environmental fac-
tors [23], it is possible that multiple genetic variants in 
the host may be involved in susceptibility to disease as 
opposed to rare genetic disorders that are often explained 
by single variants [1]. A gene ontology (GO) enrichment 
analysis was performed in order to identify possible path-
ways, as opposed to single variants, that may be involved 
in susceptibility to TB. When the 1611 SNPs identified 
in active TB cases only using the SureSelect kit were 
analyzed, several molecular pathways were identified as 
being significantly enriched (p value <0.01), including 
some with a known link to TB infection. These included 
(1) cellular response to ATP and purinergic nucleotide 
receptor signaling pathway; (2) apoptotic processes; 
and (3) vitamin metabolic and biosynthetic processes 
(Table 1). These pathways were also identified when only 
the 112 SNPs that overlap with the two kits were ana-
lyzed (data not shown).
We also interrogated our data against a previously 
reported list of variants in 26 innate immune genes 
that have been shown to be associated with susceptibil-
ity to TB [4]. For this analysis we used the entire SSTE 
SNP data set that the met the quality standards out-
lined above. We included variants identified in intron or 
intergenic regions only if sufficient coverage (10×) was 
Page 3 of 5Duncan et al. BMC Res Notes  (2015) 8:750 
present in all five samples. We identified SNPs in sev-
eral innate immune genes previously shown to be poten-
tially associated with active TB [4] (Table  2). Based on 
the SNPs identified in active TB subjects, three of these 
genes appear to be related to active TB in our study (i.e. 
TLR1, TNF and VDR). Although we identified SNPs in 
the remaining genes listed in Table  2, these were found 
in both latent and active TB cases or only in individuals 
with latent TB. Of the three genes with SNPs present in 
active TB cases but not in latent cases: toll-like recep-
tor-1 (TLR1), vitamin D receptor (VDR) and tumor 
necrosis factor (TNF), only SNPs in TLR1 were found in 
all three active cases. SNPs in these three genes were also 
confirmed by Sanger sequencing (Additional file 2). Both 
the A743G (Asn148Ser) and G1805T (Ser602Ile) variants 
were identified in TLR1. Although data regarding a link 
between TLR1 variants and susceptibility to TB is ambig-
uous [24–27], it has been shown that the 602Ser allele 
inhibits cell surface trafficking leading to a lack of TLR1 
on the plasma membrane and a hypo-responsiveness to 
TLR1 agonists including mycobacterial membrane prep-
arations [24, 25, 28]. The role of VDR and susceptibility 
to TB is also under debate [29, 30] but the active metabo-
lite of vitamin D (1,25-dihydroxyvitamin D3) suppresses 
the growth of M. tuberculosis in vitro [31, 32] and vita-
min D deficiency has been associated with susceptibil-
ity to active TB [33]. TNF is a cytokine that plays a key 
role in granuloma formation [34–36]. Neutralization of 
TNF leads to a lack of control of initial or chronic infec-
tion and loss of granuloma structure. There have been 
Table 1 Gene ontology (GO) enrichment analysis of  1611 SNPs identified at  10× coverage using SureSelect kit 
with P < 0.01
GO description Occurrences P values Link to tuberculosis
All genes Sample
Cellular response to ATP 7 4 3.23E−4 [41, 42]
Riboflavin metabolic process 5 3 1.71E−3
Regulation of centriole replication 5 3 1.71E−3
Axon guidance 281 28 2.98E−3
Vitamin E metabolic process 2 2 3.27E−3 [43]
Epithelial cell proliferation 2 2 3.27E−3
Response to cortisol stimulus 2 2 3.27E−3
Negative regulation of retinal ganglion cell axon guidance 2 2 3.27E−3
Cellular response to hormone stimulus 12 4 3.63E−3
O‑glycan processing 55 9 3.71E−3
Regulation of small GTPase mediated signal transduction 121 15 3.75E−3
Integrin‑mediated signaling pathway 37 7 4.45E−3
Purinergic nucleotide receptor signaling pathway 7 3 5.49E−3 [44]
Synaptic vesicle endocytosis 7 3 5.49E−3
Negative regulation of phosphatase activity 49 8 6.18E−3
Response to unfolded protein 30 6 6.26E−3 [45]
Autophagic vacuole fusion 8 3 8.41E−3 [46]
Nucleocytoplasmic transport 15 4 8.73E−3
Small GTPase mediated signal transduction 158 17 8.93E−3
Pre‑B cell allelic exclusion 3 2 9.43E−3
Pressure natriuresis 3 2 9.43E−3
Chemorepulsion involved in embryonic olfactory bulb interneuron precursor migration 3 2 9.43E−3
Positive regulation of telomere maintenance via telomerase 3 2 9.43E−3
Lacrimal gland development 3 2 9.43E−3
Roundabout signaling pathway 3 2 9.43E−3
Leukotriene B4 catabolic process 3 2 9.43E−3
Vitamin K biosynthetic process 3 2 9.43E−3
Metaphase plate congression 3 2 9.43E−3
Regulation of endopeptidase activity 3 2 9.43E−3
Apoptotic process involved in luteolysis 3 2 9.43E−3
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multiple conflicting studies examining the role of SNPs in 
the TNF promoter at the −308 position and TB suscepti-
bility [37–40] however there is no evidence that SNPs in 
this region effect the transcription of TNF [36]. Conflict-
ing results is not surprising in a complex diseases like TB, 
where many gene variants could be interacting to result 
in disease, and the combination of different gene variants 
could lead to the same outcome.
Impacts
The work outlined in this study was completed in 
16  months. This included review by the Ethics Board, 
training of the research nurse to recruit potential partici-
pants in one of Toronto’s under-housed shelters, recruit-
ment, sample collection, sequencing and data analysis. 
Active recruitment of participants at the shelter site was 
completed in only 1 month. However, even in that short 
period of time we were able to recruit nine potential 
participants and we anticipate that larger trials with an 
expansion in duration of recruitment as well as number 
of targeted shelters will result in a much larger participa-
tion by individuals that meet the recruitment specifica-
tions. Even though our pilot study only included three 
individuals with a history of active TB and two individu-
als with confirmed TB infection but not disease, exome 
sequencing proved to be a powerful technique to identify 
potential host genetic variants associated with suscepti-
bility to TB disease. Future studies expanding the number 
of individuals in each cohort will help narrow down the 
number of potential targets for validation.
To our knowledge, this is the first study that has used 
exome sequencing to potentially identify genomic mark-
ers of susceptibility to TB resulting in a large set of data 
including potential single nucleotide variants as well as 
molecular and cellular pathways that may be associated 
with TB infection and disease.
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